GABAA Receptor Inverse Agonists for Postoperative Memory Impairment

The invention segments the GABAA receptor into specific subunit compositions (α4βδ and α6βδ) to target memory-related functions separately from other GABAA receptor functions. By designing inverse agonists that selectively bind to δ-containing receptors, the patent isolates the therapeutic effect on memory from broader anesthetic effects, thereby improving memory reliability while managing mechanism complexity through selective targeting.

The patent applies local quality by creating receptors with specific subunit compositions (α4βδ and α6βδ) that are preferentially located in brain regions critical for memory (hippocampus and cortex). The inverse agonists selectively target these locally expressed receptor variants, improving memory function through localized action rather than global GABAA receptor modulation, thus addressing memory issues without requiring complete understanding of all anesthetic mechanisms.

The invention segments GABAA receptor modulation into selective inverse agonism at δ-containing receptors (α4βδ, α6βδ) versus modulation of other GABAA receptor subtypes. This segmentation allows cognitive improvement through memory-specific receptor targeting while preserving or reducing sedative effects that arise from broader GABAA receptor suppression, thereby decoupling cognitive benefits from unwanted sedation.

Instead of using positive modulators or agonists that enhance GABAA receptor activity (which would increase sedation), the patent employs inverse agonists that reduce activity at specific δ-containing receptors. This inverted approach—decreasing rather than increasing overall GABAA tone—selectively improves cognitive function while minimizing or reversing sedative effects, as the inverse agonism at memory-critical receptors does not produce the same sedative outcomes as traditional GABAA activation.